Stock
Ticker
First
Article
Original
Price
Price
Today
AXDX Oct 14 27.38 Check
MILL Sept 19 4.96 Check
DGLY Sept 16 20.65 Check
MNDL Aug 26 5.35 Check
FCEL Aug 20 2.76 Check
SYMX Aug 7 1.20 Check
ADES July 11 22.70 Check
TTGT June 19 8.19 Check
ANY.V May 28 9.42 Check
CYBX Apr 16 62.24 Check
OPTT Apr 4 4.19 Check
MDXG Mar 21 7.01 Check
AMRS Mar 7 4.85 Check
UNIS Feb 27 4.65 Check
PHMD Oct 17 15.49 Check
TXMD Feb 14 6.36 Check
SGMO Sept 19 11.21 Check
ZEN.V Sept 9 3.78 Check
XONE Aug 28 71.90 Check
TEAR Aug 1 14.40 Check
CNDO July 15 8.65 Check
RVLT July 2 4.03 Check
LOTE May 5 10.00 Check
LULU April 18 71.34 Check
PSSI Oct 3 23.00 Check
TNGO Aug 28 19.55 Check
MDVN May 31 $85.01 Check
JIVE May 3 $24.09 Check
SNPK April 3 $1.70 Check
QCOR Jan. 11 $41.54 Check
BRLI Nov. 1 $20.04 Check
PANL Oct. 3 $47.94 Check
GORO Aug. 23 $24.32 Check
MILL July 28 $7.04 Check
CIGX June 30 $4.51 Check
JAMN May 16 $5.17 Check
SWSH May 2 $8.77 Check
LEXG April 26 $4.02 Check
NOG March 21 $28.25 Check
VOG March 21 $5.02 Check
HNHI Feb. 17 $1.46 Check
IBIO Feb. 10 $5.17 Check
COUGF Feb. 1 $3.36 Check
LLEN Jan. 11 $10.27 Check
HHWW Dec. 23 $1.63 Check
CYDE Dec. 2 $3.29 Check
SMED Oct. 14 $5.87 Check
RMCP Sept. 21 $0.69 Check
INET Sept. 13 $10.66 Check
CLKZ Aug. 30 $0.53 Check
LQMT Aug. 19 $0.76 Check
LOCM Aug. 4 $6.12 Check
ESPH June 25 $1.49 Check
APOL June 15 $47.60 Check
BPI June 15 $19.63 Check
SILA May 27 $1.14 Check
FLPC May 27 $0.97 Check
AMEL May 27 $1.05 Check
STP May 17 $10.62 Check
BGBR April 26 $1.21 Check
NNLX April 16 $1.10 Check
CHTL April 9 $0.74 Check
AMLM March 25 $1.02 Check
LTUM March 25 $1.25 Check
TRGL March 11 $9.56 Check
TSHO Feb 24 $1.16 Check
CSKI Feb 19 $18.30 Check
GXDX Feb 15 $31.69 Check
JYHW Jan 19 $1.83 Check
AENY Jan 19 $4.51 Check
CLRH Dec 08 $1.35 Check
NXTH Dec 08 $2.28 Check
IMGG Nov 22 $1.39 Check
MEVT Nov 16 $0.35 Check
AWSL Nov 16 $3.29 Check
FRPT Oct 13 $5.84 Check
AEHI Oct. 4 $0.87 Check

The best new website for learning about penny-stock scams.

Melissa Davis, senior editor of The Street Sweeper, poses with celebrity stock picker Jim Cramer after a recent taping of his "Mad Money" television show. Davis worked as an investigative reporter for TheStreet.com, where Cramer serves as chairman, before assuming her current role at The Street Sweeper.

Vimicro: James Bond Might Say, "A Storm's Coming" For This Spy Company

by Sonya Colberg, Senior Investigative Reporter, 10/23/2014 11:50:08 AM

Vimicro International (VIMC), a Chinese company that makes video cameras for spying, has fallen under our surveillance. And investors won’t like what we’ve uncovered.

Founded in 1999 in the People’s Republic of China, the company’s video processing business quickly declined and the focus has sharpened on security video systems sold in China.

 “It’s a fairly boring hardware business,” yawned an analyst. “There are companies hundreds of times better that are in a better position … And over time, Vimicro’s margins are going to shrink further and further.”

VIMC’s stock gyrations have been anything but boring recently.

In a year of mediocrity, the stock price screamed from a few bucks to the $10 level in a spillover from investor interest in GoPro (GPRO) action camera and the Ferguson incident, as well as some VIMC hype. The stock is now above the sole analyst’s price target of $10, yet analysts we’ve spoken with think the stock is worth half that.

For this company, “A storm’s coming,” as secret agent 007 James Bond said. Here’s why we’re blowing the cover on this company that reported a $56 million net loss over the last three years:

  1. Insiders racing to sell; millions more shares may be ready to zing investors.

Options for 2.3 million shares at $0.195 expired just last week. That amounts to about 20 percent of outstanding shares.



IBIO: A Wannabe Ebola Player Infecting Buyers with False Hope

by Melissa Davis, 10/23/2014 10:02:00 AM

Shame on iBio (Nasdaq: IBIO) for pulling a dangerous stunt that could soon cost its shareholders a staggering fortune. No matter how tempted IBIO might have felt to further capitalize on the Ebola scare – or how thrilled it must be with the immediate results – the company should have known better than to hype a vague possibility so remote that it looks downright farfetched.

Get ready for the truth to unfold and reality to exact its inevitable toll.

Let’s cut to the chase and get straight to the point. In short, IBIO has suggested that its technology might play a serious role in the mass-production of a promising new Ebola drug that already utilizes a rival delivery system to handle that process instead. Since IBIO has so far tested its own delivery system on just a handful of vaccines in early-stage safety trials – and the company never even bothered to mention the word “Ebola” in its recent 92-page 10K report – the government might feel understandably reluctant to let some manufacturer casually substitute the firm’s experimental technology for the very platform used to engineer that vital treatment and simply hope that it produces the same kind of results.

Last week, in fact, the head of the government-funded lab where IBIO would like to offer its services virtually ruled out the likelihood of any changes to the existing process at all. Look at the revealing comments shared by Dr. Brett Girior, chief executive of the health science center at Texas A&M, in the following excerpt from a recent media report:

“’We believe there are substantial opportunities to increase the yield of ZMapp’ (the new Ebola treatment) in plants while keeping the product the same,’ Giroir said in an interview. The compound needs to be identical to what Mapp (the maker of the drug) has already vetted in animals, ‘or you would have to go back to the beginning for safety testing,’ he said.”

Based upon the information that we’ve uncovered while conducting our extensive research, we feel so confident that IBIO will play no role in the urgent mass-production of ZMapp that we dare the company to present any concrete evidence that clearly suggests otherwise. We also strongly encourage bullish investors to present the same type of request to IBIO or, better yet, Caliber Biotherapeutics -- the firm that IBIO likes to treat as its potential ticket to the ZMapp production line – since they have put so much money on the line. We highly doubt that they’ll feel quite so confident in their investment once they finish that exercise, but we invite them to share any feedback that might prove us wrong as well. 

JAMN Finally Spills the Beans -- And It's an Ugly Mess

by Janice Shell, 6/2/2011 10:32:51 AM

* Editor's Note: Readers can access links to additional backup documents for this story by clicking here for TheStreetSweeper's original investigative report on this company.

Late Tuesday afternoon, after missing earlier deadlines, Jammin Java (OTC: JAMN.OB) filed a long-awaited annual report packed with enough eye-opening news to keep investors up all night. That mandatory filing, unaccompanied with a cheerful press release heralding its arrival, served as a painful wake-up call to shareholders already burned by a rapid plunge in the company’s stock price.

To be sure, the 10-K offered investors little reason to sing. For starters, the filing reveals, this once-hot “coffee company” sells no coffee of its own at all. JAMN relies on a supplier based in frigid Canada – far away from the tropical Jamaican home of its co-founder Rohan Marley – to provide the company with an actual product to sell to its customers instead.

Back in April of 2010, JAMN inked a “supply and toll agreement” with Canterbury Coffee of British Columbia that gave it access to some brew. According to that agreement, JAMN relies on Canterbury to fulfill every role – save a minor one – normally satisfied by a firm that classifies itself as a coffee company. Canterbury purchases the coffee beans. It roasts them. And it then packages them in bags supplied by JAMN – the company’s only real product – for sale to the public.

JAMN signed this deal more than a year ago, right before Shane Whittle – a notorious Vancouver stock promoter – officially resigned as CEO of the company. But the company never mentioned that agreement, seemingly material enough to warrant at least a quiet 8-K report, in a single regulatory filing until now.   

Jammin Java (JAMN): Hot Stock ... Bitter Aftertaste?

by Janice Shell, 6/2/2011 10:30:25 AM

It’s time to wake up and smell the coffee! That’s exactly what Jammin Java (OTC: JAMN.OB), a heavily promotedcoffee company, and – for very different reasons – TheStreetSweeper would like investors to do.

Since the beginning of the year, JAMN has miraculously risen from the ashes of the “Grey Market” graveyard to become one of the liveliest – and richest – stocks in the entire microcap arena. JAMN has seen its stock shoot straight toward heaven, soaring from 55 cents to peak above $6 a share on massive daily volume, with its market value nowtopping $355 million despite the company’s limited resources and operating history. (As covered in more detail below, two of the Internet tout sheets pushing JAMN the hardest effectively vanished -- disabled by their Internet servers -- on the day the stock’s trading volume exploded past 20 million shares.) 

JAMN stands out for its powerful connections, the first loudly celebrated by the company and the second – involving a notorious stock promoter – carefully hidden from view.


 

CCME: Few Signs of Life at 'Healthy' Chinese Firm

by Roddy Boyd, 3/23/2011 9:30:34 AM

* Editor's Note: This story has been republished with permission from The Financial Investigator. To access the original article, complete with links to back-up documents, click here.

In the maze of thronged and narrow streets that makes up Fujian province’s capital city of Fuzhou, a deft driver, if he’s willing–as all Chinese drivers apparently are–to nearly kill or injure vast numbers of his countrymen can take you to the foot of Dongjie street. There was little reason to be there save for its having the headquarters of a company called China MediaExpress Holdings (Nasdaq: CCME), an enterprise that seems to be able to weather allegations about its business that would have forced the share price collapse of a company five times its size. The attention of bulls and bears is not misplaced: In a mere four years as a public company, it has apparently come to dominate the ad placement market for leading multinational consumer products companies on a network of what it claims is more than 27,000 buses on Chinese airport and intercity routes.

Also, and this cannot be understated, hanging out on a sidewalk in Fujian–the sidewalks double as parking spots when the streets, which appeared to have been designed in the Han Dynasty, fill up–was not a viable option. There was also the matter of the world-class headache the Financial Investigator was developing from Fuzhou’s diabolical smell, an epic conflation of poor sewage treatment, air pollution and the smell of cabbage that made getting the hell off Dongjie street a matter of vital importance.

The Financial Investigator and his traveling companion for the trip, an American investor with extensive experience in China, decided to head upstairs despite our interview with the CFO having been cancelled at the last minute (with no explanation given.) We thought a quick tour of the offices and meeting a few other executives might open our eyes to a few things.

It did.

Though the language barrier was a little steep with the young receptionist–when we asked for writing paper, she provided Kleenex–we were in short order shown to their conference room and told to wait. It did not escape notice that pride of place in the conference room belonged to a framed certificate of participation from the Fall 2010 Rodman & Renshaw conference, the World Cup for reverse merger companies and the pumpers and touts who peddle them.

Eventually chief operating officer James Yu came down and after spending 30 minutes trying to understand who we were, concluded that giving us a tour wouldn’t hurt. Soon enough, his colleague, Vinne Ye–the chairman’s assistant–came out and took us around.

It was most eye-opening.

more...

Signup For Alerts
When new stories are published
Email:  

The Street Sweeper Is Not A Fan of Glu Mobile Inc.'s Kim Kardashian Game (GLUU):

Read the Article
Read the GLUU Story

Glu Mobile Falls as Kardashian Game Drops in Rankings (GLUU):

Read the Article
Read the GLUU Story

CNBC on TheStreetSweeper's coverage of Gold Resource Corporation: (GORO):
"Herb Greenberg comments on Gold Resource Corporation"

Watch the Video
Read the GORO Story

CNBC on TheStreetSweeper's coverage of Miller Energy Resources: (MILL):
"Melissa Davis at TheStreetSweeper … wrote a piece on this thing that obviously scared investors a little bit … It was an excellent reporting job (and) has moved the stock dramatically."

Watch the Video
Read the MILL Story

Herb Greenberg's View (NOG):
"There are questions about related parties … Sometimes companies just don't pass that 'sniff test.'"

Watch the Video
Read the NOG Story

Cramer's View (SWSH): "I wouldn't touch Swisher with a 10-foot PLUNGER!"
Watch the Video
Read the SWSH Story

Cramer's View (NOG): "I clearly have been jarred by the accounting issues and feel like, right now, the momentum has left this stock."
Watch the Video
Read the NOG Story

New Article Alert! Sign up to get notified of new articles.  Click Here. Subscribe
     
| More

Investors must be properly armed in order to protect themselves against the dangers of Wall Street. To help out, The Street Sweeper has mined the Internet for the most powerful weapons available to investors researching publicly traded companies. In our “Loaded Weapons” section, you’ll find direct links to corporate documents filed with the SEC, conference call transcripts published by Seeking Alpha, insider stock sales tracked by Insider-Monitor.com and popular investment tools offered by Yahoo! Finance. You can also identify the promoters behind current penny stock campaigns – and the compensation they are receiving – by connecting to StockPromoters.com. You can link to other websites that are conducting topnotch stock investigations as well. Click here now.

When investors begin their homework on small-cap companies - particularly on penny stocks - they should probably start with an important history lesson. Specifically, they should conduct background checks on their stockbrokers and the companies those brokers are touting.
 
The Street Sweeper has designed a cheat sheet of sorts to help out with this research. Our “Rap Sheet” section links to a free tool (sponsored by FINRA) that allows ordinary investors to review the backgrounds of individual stockbrokers and their brokerage firms. The section also links to whistleblower cases and class-action lawsuits targeting publicly traded companies. It provides access to recent news of SEC enforcement actions and FBI white-collar crime investigations as well.
click here now.